×
About 243 results

ALLMedicine™ Afibrinogenemia Center

Research & Reviews  88 results

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT03793426

Oct 7th, 2022 - There is a need to increase the body of data on treatment effectiveness and safety in the ultra-rare setting of congenital fibrinogen deficiency. Real-world evidence (RWE) derived from non-interventional studies can describe product utilization, d...

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04636268

Sep 22nd, 2022 - This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia. This clinical trial is planned to ...

One Hundred Years of Congenital Fibrinogen Disorders.
https://doi.org/10.1055/s-0042-1756187
Seminars in Thrombosis and Hemostasis; Casini A, Moerloose P et. al.

Sep 3rd, 2022 - Congenital fibrinogen disorders encompass a broad range of fibrinogen defects characterized by a wide molecular and clinical spectrum. From the first clinical description of afibrinogenemia in 1920, many major achievements have contributed to a be...

Transfusion of fibrinogen concentrate before dental extractions in patients with afibri...
https://doi.org/10.2450/2022.0037-22
Blood Transfusion = Trasfusione Del Sangue; Czajkowska S, Rupa-Matysek J et. al.

Aug 16th, 2022 - Afibrinogenemia is a coagulation disorder that occurs with a frequency of 1-2 cases/1,000,000 population and is characterized by a lack of capacity to synthesize fibrinogen. The predominant symptoms related to fibrinogen deficiency are mucocutaneo...

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT02065882

Jul 27th, 2022 - The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or proph...

see more →

Drugs  2 results

Fibryga - fibrinogen (human) kit-Octapharma USA Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a93f4-d84b-1fa9-51ed-32f6140bf423

Aug 1st, 2022 - FIBRYGA is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. FIBRYGA is not indicated for dysfibrin...

Riastap - fibrinogen human injection, powder, lyophilized, for solution-CSL Behring GmbH
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc

Jun 15th, 2021 - RIASTAP®, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogen...

see more →

Clinicaltrials.gov  7 results

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT03793426

Oct 7th, 2022 - There is a need to increase the body of data on treatment effectiveness and safety in the ultra-rare setting of congenital fibrinogen deficiency. Real-world evidence (RWE) derived from non-interventional studies can describe product utilization, d...

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04636268

Sep 22nd, 2022 - This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia. This clinical trial is planned to ...

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT02065882

Jul 27th, 2022 - The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or proph...

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
https://clinicaltrials.gov/ct2/show/NCT02281500

Mar 31st, 2022 - This study is a phase I-II, multi-center, prospective, open-label, single-arm, clinical trial to evaluate Pharmacokinetic (PK), efficacy, and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in adult and pediatric participants w...

Quality of Life in Patients With Congenital Afibrinogenemia
https://clinicaltrials.gov/ct2/show/NCT03484065

Nov 12th, 2020 - In this observational study, children and adults suffering from congenital afibrinogenemia confirmed by biology will be enrolled. All patients will receive a questionnaire on quality of life in their own language during a routine visit and filled ...

see more →